LEMAITRE VASCULAR, INC. Excess Tax Benefit from Share-based Compensation, Financing Activities
LEMAITRE VASCULAR, INC. (LMAT) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $454.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2018-03-09.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2018-03-09
- LEMAITRE VASCULAR, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2014-12-31 was $197.00K.
- LEMAITRE VASCULAR, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2014-09-30 was $0.00.
- LEMAITRE VASCULAR, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2014-06-30 was $0.00.
- LEMAITRE VASCULAR, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2014-03-31 was $28.00K.
- LEMAITRE VASCULAR, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2015 was $454.00K, a 101.78% increase from fiscal 2014.
- LEMAITRE VASCULAR, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2014 was $225.00K, a 625.81% increase from fiscal 2013.
- LEMAITRE VASCULAR, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2013 was $31.00K, a 34.78% increase from fiscal 2012.
- LEMAITRE VASCULAR, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2012 was $23.00K, a 54.00% decline from fiscal 2011.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month |
|---|---|---|---|---|
| 2015-12-31 | $454.00K 10-K · filed 2018-03-09 | |||
| 2014-12-31 | $197.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $197.00K derived: sum of 2 quarters · filed 2017-03-09 | $197.00K derived: sum of 3 quarters · filed 2017-03-09 | $225.00K 10-K · filed 2017-03-09 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $0.00 derived: sum of 2 quarters · filed 2015-11-06 | $28.00K 10-Q · filed 2015-11-06 | |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $28.00K 10-Q · filed 2015-08-06 | ||
| 2014-03-31 | $28.00K 10-Q · filed 2015-05-07 | |||
| 2013-12-31 | $31.00K 10-K · filed 2016-03-10 | |||
| 2012-12-31 | $23.00K 10-K · filed 2015-03-18 | |||
| 2011-12-31 | $50.00K 10-K · filed 2014-03-21 | |||
| 2010-12-31 | $70.00K 10-K · filed 2013-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NovoCure Ltd (NVCR) | $1.886B | -11.87 | |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |